199 related articles for article (PubMed ID: 27207978)
1. Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry.
Lovsin Barle E; Winkler GC; Glowienke S; Elhajouji A; Nunic J; Martus HJ
Toxicol Sci; 2016 May; 151(1):2-9. PubMed ID: 27207978
[TBL] [Abstract][Full Text] [Related]
2. A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.
Hayes EP; Jolly RA; Faria EC; Barle EL; Bercu JP; Molnar LR; Naumann BD; Olson MJ; Pecquet AM; Sandhu R; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S39-47. PubMed ID: 27267172
[TBL] [Abstract][Full Text] [Related]
3. Derivation of Occupational Thresholds of Toxicological Concern for Systemically Acting Noncarcinogenic Organic Chemicals.
Chebekoue SF; Krishnan K
Toxicol Sci; 2017 Nov; 160(1):47-56. PubMed ID: 29036659
[TBL] [Abstract][Full Text] [Related]
4. A scoping survey of attitudes towards occupational exposure limits and REACH derived no effect levels for workers among chemical risk managers at Swedish workplaces.
Schenk L
Int J Occup Med Environ Health; 2020 Sep; 33(5):611-620. PubMed ID: 32699425
[TBL] [Abstract][Full Text] [Related]
5. Setting occupational exposure limits for pharmaceuticals.
Naumann BD; Sargent EV
Occup Med; 1997; 12(1):67-80. PubMed ID: 9153053
[TBL] [Abstract][Full Text] [Related]
6. Industry Derived Occupational Exposure Limits: A Survey of Professionals on the Dutch System of Exposure Guidelines.
Schenk L; Visser MJ; Palmen NGM
Ann Work Expo Health; 2019 Nov; 63(9):1004-1012. PubMed ID: 31504142
[TBL] [Abstract][Full Text] [Related]
7. Disease area and mode of action as criteria to assign a default occupational exposure limit.
Glogovac M; Paulson C; Lambert A; Winkler GC; Lovsin Barle E
Regul Toxicol Pharmacol; 2021 Jun; 122():104891. PubMed ID: 33587935
[TBL] [Abstract][Full Text] [Related]
8. The occupational exposure level (OEL) for 2-bromopropane: the first OEL established by Korea.
Yu IJ; Kim HY; Lim CH; Lee YM; Moon YH
Appl Occup Environ Hyg; 1999 Jun; 14(6):356-8. PubMed ID: 10429728
[No Abstract] [Full Text] [Related]
9. Approaches for setting occupational exposure limits in the pharmaceutical industry.
Ahuja V; Krishnappa M
J Appl Toxicol; 2022 Jan; 42(1):154-167. PubMed ID: 34254327
[TBL] [Abstract][Full Text] [Related]
10. Advances in Inhalation Dosimetry Models and Methods for Occupational Risk Assessment and Exposure Limit Derivation.
Kuempel ED; Sweeney LM; Morris JB; Jarabek AM
J Occup Environ Hyg; 2015; 12 Suppl 1(sup1):S18-40. PubMed ID: 26551218
[TBL] [Abstract][Full Text] [Related]
11. Use of the benchmark-dose (BMD) approach to derive occupational exposure limits (OELs) for genotoxic carcinogens: N-nitrosamines.
Blum K; FitzGerald R; Wilks MF; Barle EL; Hopf NB
J Appl Toxicol; 2023 Aug; 43(8):1183-1200. PubMed ID: 36840679
[TBL] [Abstract][Full Text] [Related]
12. Using default methodologies to derive an acceptable daily exposure (ADE).
Faria EC; Bercu JP; Dolan DG; Morinello EJ; Pecquet AM; Seaman C; Sehner C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S28-38. PubMed ID: 27233926
[TBL] [Abstract][Full Text] [Related]
13. Strategy of the scientific committee on occupational exposure limits (SCOEL) in the derivation of occupational exposure limits for carcinogens and mutagens.
Bolt HM; Huici-Montagud A
Arch Toxicol; 2008 Jan; 82(1):61-4. PubMed ID: 18008062
[TBL] [Abstract][Full Text] [Related]
14. Background, approaches and recent trends for setting health-based occupational exposure limits: a minireview.
Nielsen GD; Ovrebø S
Regul Toxicol Pharmacol; 2008 Aug; 51(3):253-69. PubMed ID: 18502550
[TBL] [Abstract][Full Text] [Related]
15. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
16. OELs derivation in Poland and in the former Eastern Bloc with reference to approaches and practices applied in the EU.
Soćko R; Czerczak S; Kupczewska-Dobecka M
Med Pr; 2015; 66(3):383-92. PubMed ID: 26325051
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk of immunosuppressants in manufacturing.
Barle EL; Winkler GC; Ulrich P; Perino C; Kuster M; Probst A; Thielen S; Bechter R
Regul Toxicol Pharmacol; 2014 Oct; 70(1):122-4. PubMed ID: 24997232
[TBL] [Abstract][Full Text] [Related]
18. [Theory and practice of primary cancer prevention].
Tompa A
Magy Onkol; 2007; 51(1):7-21. PubMed ID: 17417671
[TBL] [Abstract][Full Text] [Related]
19. Derived no-effect levels (DNELs) under the European chemicals regulation REACH--an analysis of long-term inhalation worker-DNELs presented by industry.
Schenk L; Deng U; Johanson G
Ann Occup Hyg; 2015 May; 59(4):416-38. PubMed ID: 25471229
[TBL] [Abstract][Full Text] [Related]
20. A comparison of REACH-derived no-effect levels for workers with EU indicative occupational exposure limit values and national limit values in Finland.
Tynkkynen S; Santonen T; Stockmann-Juvala H
Ann Occup Hyg; 2015 May; 59(4):401-15. PubMed ID: 25638729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
